Program Area: Therapeutics Threat Area: COVID-1

Program Area: Therapeutics

Threat Area: COVID-19

Description:
Regeneron is developing a monoclonal antibody (mAb) therapeutic candidate for pre-exposure prophylaxis (PrEP) designed to neutralize all circulating virus variants, including recent Omicron subvariants. The investigational mAb binds to a conserved region of the virus, thus decreasing the risk of losing activity as the virus evolves over time and has a half-life extension to provide long-acting prevention.

Look at how much money they are throwing at this.


“Unique Impact:
Pre-exposure prophylaxis (PrEP) is a therapeutic option for preventing infection in individuals who are immune compromised or who are not protected adequately by vaccination. Currently there are no U.S. Food and Drug Administration (FDA)-approved PrEP therapeutics for COVID-19, meaning novel monoclonal antibodies could fill a critical gap in protecting individuals at high risk for COVID-19 complications.


Base Award Amount: $326,475,498.00 (August 22, 2023)

Cost Share: Yes”

https://medicalcountermeasures.gov/nextgen